Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 5th edition, 486 pages

Free download

  Prostate Cancer

  Free Subscription


3 Anticancer Res
3 BJU Int
1 BMC Cancer
1 BMC Urol
1 Br J Cancer
1 Br J Radiol
1 Cancer
1 Cancer Imaging
1 Cancer Res
1 Eur J Radiol
3 Eur Urol
2 Hum Pathol
2 Int J Urol
8 J Urol
3 Oncol Rep
4 PLoS One
1 Prog Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Anticancer Res

  1. OGASAWARA N, Nakiri M, Kurose H, Ueda K, et al
    Longitudinal Changes in Health-related Quality of Life After (125)I Low-dose-rate Brachytherapy for Localized Prostate Cancer.
    Anticancer Res. 2020;40:6443-6456.
    PubMed         Abstract available

  2. SIVONOVA MK, Jurecekova J, Kaplan P, Hives M, et al
    Association of MDM2 T309G (rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population.
    Anticancer Res. 2020;40:6257-6264.
    PubMed         Abstract available

  3. BAI L, Li X, Ma X, Zhao R, et al
    In Vitro Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells.
    Anticancer Res. 2020;40:6051-6062.
    PubMed         Abstract available

    BJU Int

  4. SEETHARAM BHAT KR, Moschovas MC, Onol FF, Sandri M, et al
    Trends in clinical and oncological outcomes of robot-assisted radical prostatectomy before and after the 2012 US Preventive Services Task Force recommendation against PSA screening: a decade of experience.
    BJU Int. 2020;125:884-892.
    PubMed         Abstract available

  5. SIGHINOLFI MC, Eissa A, Spandri V, Puliatti S, et al
    Positive surgical margin during radical prostatectomy: overview of sampling methods for frozen sections and techniques for the secondary resection of the neurovascular bundles.
    BJU Int. 2020;125:656-663.
    PubMed         Abstract available

  6. YAMAMOTO A, Kato M, Hattori K, Naito Y, et al
    Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
    BJU Int. 2020;125:702-708.
    PubMed         Abstract available

    BMC Cancer

  7. MENG Y, Hu X, Li S, Zeng X, et al
    miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1.
    BMC Cancer. 2020;20:1028.
    PubMed         Abstract available

    BMC Urol

  8. WILLIAMS SG, Aw Yeang HX, Mitchell C, Caramia F, et al
    Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report.
    BMC Urol. 2020;20:171.
    PubMed         Abstract available

    Br J Cancer

  9. LOZANO R, Castro E, Aragon IM, Cendon Y, et al
    Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01114.
    PubMed         Abstract available

    Br J Radiol

  10. PILIERO MA, Casiraghi M, Bosetti DG, Cima S, et al
    Patient-based low dose cone beam CT acquisition settings for prostate image-guided radiotherapy treatments on a Varian TrueBeam linear accelerator.
    Br J Radiol. 2020 Aug 27:20200412. doi: 10.1259/bjr.20200412.
    PubMed         Abstract available


  11. FILSON CP, Hong F, Xiong N, Pozzar R, et al
    Decision support for men with prostate cancer: Concordance between treatment choice and tumor risk.
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33241.
    PubMed         Abstract available

    Cancer Imaging

  12. PRICOLO P, Ancona E, Summers P, Abreu-Gomez J, et al
    Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels.
    Cancer Imaging. 2020;20:77.
    PubMed         Abstract available

    Cancer Res

  13. SAWANT DESSAI A, Palestino Dominguez M, Chen UI, Hasper J, et al
    Transcriptional repression of SIRT3 potentiates mitochondrial aconitase activation to drive aggressive prostate cancer to the bone.
    Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1708.
    PubMed         Abstract available

    Eur J Radiol

  14. LEE CH
    PIRADS v2.1: Value of diffusion-weighted imaging for PIRADS scoring of transition zone lesions.
    Eur J Radiol. 2020;129:109117.

    Eur Urol

  15. MCHENRY MB, Drake CG, Fizazi K
    Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metas
    Eur Urol. 2020 Oct 26. pii: S0302-2838(20)30789.

  16. SUN Y, Sun F, Wei Q, Huang J, et al
    Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6.
    Eur Urol. 2020 Oct 26. pii: S0302-2838(20)30779.

  17. LUDMIR EB, McCaw ZR, Wei LJ
    Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Surviv
    Eur Urol. 2020 Oct 24. pii: S0302-2838(20)30776.

    Hum Pathol

  18. HAFFNER MC, Salles DC, Gao G, Epstein JI, et al
    Gleason pattern 4 with cribriform morphology on biopsy is associated with adverse clinicopathological findings in a prospective radical prostatectomy cohort.
    Hum Pathol. 2020;98:74-80.
    PubMed         Abstract available

  19. ACOSTA AM, Taplin ME, Mata DA, D'Amico AV, et al
    Volume of Gleason pattern 4 stratifies risk of metastasis and death in patients with Gleason score 3+5=8/5+3=8 positive prostate core biopsies.
    Hum Pathol. 2020;99:62-74.
    PubMed         Abstract available

    Int J Urol

  20. MATSUOKA Y, Uehara S, Yoshida S, Tanaka H, et al
    Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems.
    Int J Urol. 2020 Oct 27. doi: 10.1111/iju.14410.

  21. SUGIURA M, Sato H, Kanesaka M, Imamura Y, et al
    Epigenetic modifications in prostate cancer.
    Int J Urol. 2020 Oct 27. doi: 10.1111/iju.14406.
    PubMed         Abstract available

    J Urol

  22. RODRIGUEZ SOCARRAS ME, Gomez Rivas J, Cuadros Rivera V, Reinoso Elbers J, et al
    Prostate Mapping for Cancer Diagnosis: The Madrid Protocol. Transperineal Prostate Biopsies Using Multiparametric Magnetic Resonance Imaging Fusion and Micro-Ultrasound Guided Biopsies.
    J Urol. 2020;204:726-733.
    PubMed         Abstract available

  23. BASILE G, Bandini M
    Editorial Comment.
    J Urol. 2020;204:967-968.

  24. BORGES RC, Tourinho-Barbosa RR, Glina S, Macek P, et al
    Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence.
    J Urol. 2020 Aug 17:101097JU0000000000001327. doi: 10.1097/JU.0000000000001327.
    PubMed         Abstract available

    Editorial Comment.
    J Urol. 2020;204:948-949.

  26. CATHELINEAU X, Sanchez-Salas R
    Editorial Comment.
    J Urol. 2020;204:949.

  27. LISS MA, Newcomb LF, Zheng Y, Garcia MP, et al
    Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study.
    J Urol. 2020;204:701-706.
    PubMed         Abstract available

  28. SCHMIDT A, Warmann SW, Eckert F, Ellerkamp V, et al
    The Role of Reconstructive Surgery and Brachytherapy in Pediatric Bladder/Prostate Rhabdomyosarcoma.
    J Urol. 2020;204:825-834.
    PubMed         Abstract available

    Editorial Comment.
    J Urol. 2020;204:967.


    No Mortality Differences Among Localized Prostate Cancer Treatments.
    JAMA. 2020;324:1599.

    Oncol Rep

  31. BAI S, Chen T, Yu X, Luo M, et al
    [Corrigendum] The specific killing effect of matrine on castrationresistant prostate cancer cells by targeting the Akt/FoxO3a signaling pathway.
    Oncol Rep. 2020 Sep 29. doi: 10.3892/or.2020.7784.
    PubMed         Abstract available

  32. XU X, Zhu Z, Xu Y, Tian S, et al
    Effects of zinc finger protein 403 on the proliferation, migration and invasion abilities of prostate cancer cells.
    Oncol Rep. 2020 Oct 1. doi: 10.3892/or.2020.7786.
    PubMed         Abstract available

  33. SHIMIZU K, Matsumoto H, Hirata H, Ueno K, et al
    ARHGAP29 expression may be a novel prognostic factor of cell proliferation and invasion in prostate cancer.
    Oncol Rep. 2020 Oct 15. doi: 10.3892/or.2020.7811.
    PubMed         Abstract available

    PLoS One

  34. KATONGOLE P, Sande OJ, Yusuf M, Joloba M, et al
    Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2015 and 2019 at the Uganda Cancer Institute.
    PLoS One. 2020;15:e0236458.
    PubMed         Abstract available

  35. ZWAANS BMM, Nicolai HE, Chancellor MB, Lamb LE, et al
    Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine.
    PLoS One. 2020;15:e0241388.
    PubMed         Abstract available

  36. BAIO G, Fabbi M, Cilli M, Rosa F, et al
    Manganese-enhanced MRI (MEMRI) in breast and prostate cancers: Preliminary results exploring the potential role of calcium receptors.
    PLoS One. 2020;15:e0224414.
    PubMed         Abstract available

  37. SINGH JP, Dagar M, Dagar G, Kumar S, et al
    Activation of GPR56, a novel adhesion GPCR, is necessary for nuclear androgen receptor signaling in prostate cells.
    PLoS One. 2020;15:e0226056.
    PubMed         Abstract available

    Prog Urol

  38. KAULANJAN K, Thenault R, Leroy V, Khene Z, et al
    [Management of hormone deprivation therapies in prostate cancer: Role of the nurse].
    Prog Urol. 2020 Oct 24. pii: S1166-7087(20)30600.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.